IL-6 quartiles^{*} (pg/mL) | Adenoma recurrence (T4) | ||||||
---|---|---|---|---|---|---|---|

No | Advanced | High-risk | Any | ||||

n (%) | n (%) | OR (95% CI)^{†} | n (%) | OR (95% CI)^{†} | n (%) | OR (95% CI)^{†} | |

Trial (T1,3) | |||||||

Q1: >2.80 | 125 (57.6) | 15 (6.9) | 1.00 | 35 (16.1) | 1.00 | 92 (42.4) | 1.00 |

Q2: 1.99-2.80 | 127 (58.3) | 12 (5.5) | 0.79 (0.34-1.81) | 26 (11.9) | 0.71 (0.39-1.27) | 91 (41.7) | 1.01 (0.68-1.49) |

Q3: 1.47-1.98 | 131 (60.1) | 16 (7.3) | 1.19 (0.53-2.63) | 26 (11.9) | 0.82 (0.45-1.48) | 87 (39.9) | 1.01 (0.68-1.49) |

Q4: <1.47 | 141 (64.4) | 6 (2.7) | 0.51 (0.19-1.41) | 13 (5.9) | 0.45 (0.22-0.92) | 78 (35.6) | 0.95 (0.63-1.42) |

P-trend^{‡} | 0.38 | 0.05 | 0.80 | ||||

Change (T1,3-T0) | |||||||

Q1: >0.55 | 123 (56.7) | 14 (6.5) | 1.00 | 33 (15.2) | 1.00 | 94 (43.3) | 1.00 |

Q2: 0.06-0.55 | 129 (59.2) | 17 (7.8) | 1.39 (0.63-3.06) | 24 (11.0) | 0.76 (0.42-1.41) | 89 (40.8) | 0.98 (0.66-1.45) |

Q3:-0.43-0.05 | 131 (60.1) | 10 (4.6) | 0.83 (0.34-2.00) | 24 (11.0) | 0.79 (0.43-1.45) | 87 (39.9) | 0.98 (0.66-1.45) |

Q4: <−0.43 | 141 (64.4) | 8 (3.7) | 0.47 (0.19-1.18) | 19 (8.7) | 0.44 (0.23-0.84) | 78 (35.6) | 0.72 (0.48-1.06) |

P-trend^{‡} | 0.06 | 0.02 | 0.09 |

*IL-6 concentrations in quartiles (Q1-Q4) of the geometric mean values of year 1 and year 3 values [Trial (T1,3)] and of the change in IL-concentrations from baseline [Change (T1,3-T0)].

^{†}Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58-66, >66 y), sex, average BMI (<25, 25.0-29.9, ≥30 kg/m^{2}), and current smoking status during the first 3 trial years.↵

^{‡}The ln[ln(value + 1)]–transformed median concentrations of each quartile were used as a continuous score variable to determine the*P*value for trend for the IL-6 concentrations at T1,3. The median concentrations of each quartile were used to determine the*P*value for trend for the change in IL-6 concentrations (T1,3-T0).